June 08, 2022



Nifty Outlook

Markets inched lower and lost nearly a percent amid mixed cues. Initially, weakness in the global markets was weighing on the sentiment and continued selling in banking, FMCG and IT majors kept the pressure intact till the end. Eventually, the Nifty ended with a cut of nearly 1% to close at 16,416 levels. The broader indices, midcap and smallcap, ended lower and lost in the range of 0.6%-0.8%.

The focus will be on MPC's meeting outcome on Wednesday amid the expectation of a further rate hike. Besides, their outlook on growth and inflation holds importance. Traders should maintain extra caution in rate-sensitive and prefer less volatile stocks for day trade. On the index front, the bias would again turn negative below 16,300 else consolidation would continue with the upper band at the 16500-16700 zone.

	VWAP (Expiry till date)	Max OI (Call)	Max OI (Put)
NIFTY	16400	17000	16000
News			

- Aurobindo Pharma announced that its wholly owned subsidiary company, Eugia Pharma Specialties has received a final approval from USFDA to manufacture and market Leuprolide Acetate Injection, 14 mg/2.8 mL MDV (Kit). Leuprolide Acetate Injection, 14 mg/2.8 mL (1 mg/0.2 mL), Multiple-Dose Vials, to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Lupron Injection, 14 mg/2.8 mL (1 mg/0.2 mL), of AbbVie Endocrinology Inc.
- **HG Infra** has received the Letter of Award from **Adani Road Transport ltd** for the project in the State of Uttar Pradesh for the contract price of Rs 4970.99cr.
- **Ashoka Buildcon** receives Letter of Acceptance for a project worth USD 106.4mn from the Government of the co-operative Republic of Guyana. The project is for Procurement of Phase 1: East Bank-East Coast Road Linkage Project (Ogle to Haags Bosch, Eccles) and the construction period is 730 days from the date of commencement.

Derivative Ideas **								
Instrument	B/S	Lot	INITIATION RANGE	SL	TARGET			
VOLTAS	BUY 980 PE	500	28-30	17	50			

Sectors to watch					
Sector Name	Outlook				
IT	BEARISH				
BANKS	BEARISH				
FMCG	BEARISH				



Scrip	Buy/Sell	СМР	Initiation Range	SL*	Target
HINDUNILVR	BUY 2200 PE	56	50-54	30	90

In line with the recent fall in the index, **HINDUNILVER** is also witnessing profit-taking, after retesting the resistance zone around 2400 levels. It has breached the lower range of the rising channel on Tuesday i.e. June 7 and also slipped below the support zone of the moving averages ribbon i.e.(100&50)EMA on the daily chart. We thus suggest initiating fresh shorts through the Put option.

^{**}Please note that the given technical and derivative recommendations are "valid for taking position" only on recommended date and in the given range.

^{*}Please note - Stoploss is on closing basis for delivery recommendation and intraday basis for F/O recommendation.



Derivative Ideas

VOLTAS shed 1.27% and closed at 999.55 on 7th Jun. The stock has been witnessing huge selling pressure after finding resistance at 1350 levels. The down move was supported by good volumes and huge addition of Shorts in the FUTS. After some Dead Cat Bounce, the stock has resumed its correction with marginal rise in OI implying more comfort in Shorts. We expect VOLTAS to test 920 levels in the immediate short term and thus suggest initiating Shorts with the PE option.

FII & DII Cash Segment (Rs. in Cr.)							
Category Amt. MTD FYTD							
FII**	-2397	-8548	-232961				
DII**	1940	5424	189790				

**Provisiona	l data as on 06 th June.	2022
^^Provisiona	l data as on ub-june.	2022

Trade Stats						
	NO OF CONTRACTS	TURNOVER IN CR				
IDXFUTS	385959	32556				
IDXOPT	74436812	6347311				
STKFUTS	641103	39874				

Religare High Conviction Idea - CCL Products Ltd.

Scrip	СМР	Recommendation Price	Target	Duration
CCL Products Ltd.	365.30	350	496	9-12 Months

- ♦ CCL product reported revenue growth of 13.5% YoY to Rs 376cr. EBITDA declined by 1.1% YoY to Rs 84cr and margin was down by 330bps due to increase in overall expenditure. However, PAT witnessed a growth of 7.1% YoY as other income was higher by 9.5% YoY plus there was decline in interest and taxes by 19.8% YoY and 31.6%, respectively.
- From a long term perspective we have a positive view on CCL given its focus on exports, shift to B2C segment, driving volumes and gaining market share both in domestic and international markets. Further, building branded business by innovation and increasing distribution and expanding capacity will aid in gaining high revenue and margins. On the financial front, we have estimated its revenue/PAT to grow at a CAGR of 14.5%/18.4% in FY22-24E. Overall, we are optimistic on the company's growth prospect and have maintained a buy rating but have revised target price to Rs 496.

CACT Calend	ar - June 2022 (E	.G.M.)				
Sun	Mon	Tue	Wed	Thu	Fri	Sat
05	06	07	08	09	10	11
			Jagsonpal Pharmaceuticals Ltd.			

CACT Calendar - June 2022 (Bonus Issue)									
Sun	Mon	Tue	Wed	Thu	Fri	Sat			
05	Nintec Systems LtdVarun Beverages Ltd	07	08	O9Au Small Finance Bank Ltd	10	11			

June 08, 2022



Resu	lts Calendar - June 2022					
Sun	Mon	Tue	Wed	Thu	Fri	Sat
05	 Alpha Hi-Tech Fuel Ltd. Apt Packaging Ltd. Arihant Institute Ltd Chadha Papers Ltd. Cinevista Ltd. Ind-Agiv Commerce Ltd. Urja Global Ltd. Virtual Global Education Ltd. 	 Bombay Rayon Fashions Ltd. Genesys International Corporation Ltd. Mac Hotels Ltd Polo Hotels Ltd. 	08 ■ Unitech Ltd.	09	10	11 • Astron Paper & Board Mill Ltd

un	Mon	Tue	Wed	Thu	Fri	Sat
06 •		 O7 General Insurance Corporation Of India Pearl Global Industries Limited 	08 • Kansai Nerolac Paints Ltd.	 Thu O9 Craftsman Automation Ltd Elecon Engineering Co.Ltd. Elecon Engineering Co.Ltd. Hdfc Asset Management Company Ltd India Motor Parts & Accessories Ltd. Power Finance Corporation Ltd. Quess Corp Ltd Silver Touch Technologies Ltd Smc Global Securities Ltd Tata Consumer Products Ltd Transcorp International Ltd. 	• Ceat Ltd. • Lkp Finance Limited • Lkp Securities Ltd • Sagarsoft (India) Ltd • Shree Digvijay Cement Co.Ltd. • Tata Communications Ltd.	



CACT Cale	ndar - June 2022 (Amalga	mation)				
Sun	Mon	Tue	Wed	Thu	Fri	Sat
05	Gallantt Ispat Ltd.	Aar Commercial Company Ltd	08	09	10	11

CACT Cale	endar - June 2022 (Right Is	sue of Equity Shares)				
Sun	Mon	Tue	Wed	Thu	Fri	Sat
05	06	07	08	09	10	11
	• Satyam Silk Mills Ltd.					

CACT Cal	endar - Jun	ne 2022 (St	ock Split)			
Sun	Mon	Tue	Wed	Thu	Fri	Sat
05	06	07	G G Engineering Ltd	09	Sadhna Broadcast Ltd	11

Economic Ca	alendar (India) - June 2022					
Sun	Mon	Tue	Wed	Thu	Fri	Sat
05	06	07	08	09	10	11
	RBI MPC Meeting Minutes	RBI MPC Meeting Minutes	Cash Reserve Ratio			
			Interest Rate Decision			
			Reverse REPO Rate			

June 08, 2022



Religare Investment Call	S
--------------------------	---

Name of the Company	Reco Date	Current Rating*	Product Type	Reco Price	Target Price	Upside %	СМР	Expected returns from CMP %
Britannia Industries	16-Aug-2021	Buy	High Conviction Ideas	3,640	4,265	17.2%	3,383	26.1%
Nippon Life IndiaAsset Management	23-Aug-2021	Buy	High Conviction Ideas	391	492	25.8%	277	77.8%
PCBL	13-Sep-2021	Buy	High Conviction Ideas	123	153	24.4%	106	45.0%
Orient Electric	22-Sep-2021	Buy	High Conviction Ideas	344	439	27.6%	275	59.6%
Crompton Greaves Consumer Electricals	29-Oct-2021	Buy	Diwali Picks 2021	466	577	23.8%	360	60.5%
JK Lakshmi Cement	29-Oct-2021	Buy	Diwali Picks 2021	610	758	24.3%	417	81.8%
Kajaria Ceramics	29-Oct-2021	Buy	Diwali Picks 2021	1,201	1,459	21.5%	990	47.4%
Polycab India	29-Oct-2021	Buy	Diwali Picks 2021	2,269	2,890	27.4%	2,418	19.5%
Vguard Industries	29-Oct-2021	Buy	Diwali Picks 2021	261	321	23.0%	233	37.5%
Kansai Nerolac Paints	18-Nov-2021	Buy	High Conviction Ideas	605	705	16.5%	408	72.7%
Bharti Airtel	28-Dec-21	Buy	New Year Picks 2022	676	863	27.7%	685	25.9%
Biocon	28-Dec-21	Buy	New Year Picks 2022	357	437	22.4%	317	38.0%
Birlasoft	28-Dec-21	Buy	New Year Picks 2022	527	639	21.3%	361	76.8%
Clean Science and Technology	28-Маг-22	Buy	Thematic Basket - IPOs	1,991	2,509	26.0%	1,781	40.9%
Heranba Industries	28-Mar-22	Buy	Thematic Basket - IPOs	635	832	31.1%	576	44.6%

*Current rating is based on returns potential

Buy - Potential Returns >10% over 12 months

Hold - Potential Returns <10% over 12 months

For Religare Investment calls performance Click here

June 08, 2022



	Investmen	

Name of the Company	Reco Date	Current Rating*	Product Type	Reco Price	Target Price	Upside %	СМР	Expected returns from CMP %
Medplus Health Services	28-Mar-22	Buy	Thematic Basket - IPOs	957	1,215	27.0%	829	46.6%
United Spirit (MCDOWELL-N)	01-Арг-22	Buy	High Conviction Ideas	888	1,093	23.1%	790	38.3%
Exide Industries	06-May-22	Buy	High Conviction Ideas	149	229	54.4%	148	54.5%
HCL Technologies	09-May-22	Buy	High Conviction Ideas	1,050	1,333	26.9%	1,023	30.3%
Astral	11-May-22	Buy	High Conviction Ideas	1,850	2,297	24.2%	1,667	37.8%
Godrej Consumer Products	20-May-22	Buy	High Conviction Ideas	796	1,178	48.0%	750	57.1%
Ashok Leyland	23-May-22	Buy	High Conviction Ideas	130	155	19.2%	140	10.9%
The Ramco Cements	24-May-22	Buy	High Conviction Ideas	680	1,103	62.2%	610	80.8%
Metropolis Healthcare	26-May-22	Buy	High Conviction Ideas	1,573	2,731	73.6%	1,594	71.4%
Whirlpool of India	27-May-22	Buy	High Conviction Ideas	1,504	2,379	58.2%	1,586	50.0%
Sudarshan Chemical Industries	30-May-22	Buy	High Conviction Ideas	447	673	50.6%	455	47.9%
Mahindra & Mahindra	31-May-22	Hold	High Conviction Ideas	998	1,087	8.9%	1,043	4.3%
CCL Products (India)	30-May-22	Buy	High Conviction Ideas	350	496	41.7%	365	35.8%
Berger Paints	31-May-22	Buy	High Conviction Ideas	605	900	48.8%	581	54.9%
CSB Bank	07-Jun-2022	Buy	High Conviction Ideas	184	261	42.1%	181	43.8%

*Current rating is based on returns potential

Buy - Potential Returns >10% over 12 months

Hold - Potential Returns <10% over 12 months

For Religare Investment calls performance <u>Click here</u>



Research Product Basket

- For every client, the advisor must allocate a specific proportion of funds for trading and investing depending on the risk taking ability and willingness of the client and their investment goals.
- The below mentioned product basket tries to address the way to deal with the trading portfolio (cash/derivative) for optimum effectiveness of research calls.
- It is recommended to divide your trading funds for various types of calls and not invest the entire amount for 1 or 2 calls only.

		For cash	n market trading			For 1L m	argin*
Call / Product	Call Frequency	No. of calls	% funds allocated		Total	Per Call	
Intraday Calls	Intraday	2 - 3	< 1 day	25%		25,000	8,000
Live / RMD Calls	Daily	3 - 4	3 - 4 days	30%		30,000	4,000
Master Pick	Weekly	1	1 month	15%		15,000	5,000
Religare Alpha	Opportunity	NA	2 - 3 months	20%		20,000	As per weightage
Cash		NA		10%		10,000	
Intraday Calls			•	pose of squaring off positions on the d be allocated accordingly to have pro		• • • •	estrict our intraday
Live / RMD Calls		ch calls are mad		Additionally as per market opportuni ht be open for 3-4 days. Funds should			
Master Pick				f techno-funda analysis. 15% of functions for this call will be 1 mo			located for Master
Religare Alpha	•		hich are held with a view of overall trading portfolio.	2-3 months. It is recommended to al	loca	te 20% of funds for bui	lding this portfolio
Cash	10% surplus cash i	n the partfalia s	hould be kept for the purpo	ses of allocating it to opportunities a	s an	nd when they arrive	

		For derivative n	narket trading		For 1L ma	argin*
Call / Product	Call Frequency	No. of calls	% funds allocated	Total	Per Call	
Derivative Ideas	Daily	1 - 2	1 - 3 days	40%	40,000	40,000
Live calls	Intraday / Daily	1 - 2	3 - 4 days	50%	50,000	50,000
Cash		NA		10%	10,000	
Derivative Ideas			v. It can be a plain vanilla F&O be calls are open for 3-4 days on		egy. Funds should be allo	ocated assuming 2
Live Calls			ODIN during live market hours e open at any time. 3/4 times, th			s. Funds should be
Cash	It is recommended to	hold 10% cash to	capitalize on any opportunity th	nat may arise in markets.		

June 08, 2022



Research Analysts

Siddarth Bhamre siddarth.bhamre@religare.com

Ajit Mishra ajit.mishra@religare.com

Manoj M Vayalar manoj.vayalar@religare.com

Nirvi Ashar nirvi.ashar@religare.com

Rohit Khatri rohit.khatri@religare.com

Suhanee Shome suhanee.shome@religare.com

Gaurav Arora gaurav.arora3@religare.com

June 08, 2022



Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: https://www.religareonline.com/disclaimer

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation-Research Analyst (RA)

[Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F (a) to F(j) below, are given separately]

S. No.	Statement	An	swer
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one per cent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public		No
	appearance? I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest (if answer to F (a) above is Yes :

Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F (a) to F(j) above, are given below]

	SSNo.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No.
F						

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results